(Q24235351)

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Artemisinin combination therapy for vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Comparison of artesunate and chloroquine activities against Plasmodium vivax gametocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

The pathophysiology of vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Prevention and treatment of vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Resistance to therapies for infection by Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Artemisinin Resistance in Plasmodium falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Primaquine for preventing relapses in people with Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

A trial of combination antimalarial therapies in children from Papua New Guinea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Mixed-species malaria infections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Effects of artemisinin derivatives on malaria transmissibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Artemisinin-based combination therapy for treating uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Antimalarial Drug Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Averting a malaria disaster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

The assessment of antimalarial drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Mefloquine in infants and young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Therapeutic responses to different antimalarial drugs in vivax malaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Primaquine resistance in Plasmodium vivax

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

The neglected burden of Plasmodium vivax malaria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Artemisinin-based combination treatment of falciparum malaria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Vivax malaria: neglected and not benign

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008492.PUB2

7 January 2021

10.1002/14651858.CD008492.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_eqphed65c5cbhfnjuhvrofghuy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eqphed65c5cbhfnjuhvrofghuy

24 November 2022